津药药业：11月28日召开董事会会议

Group 1 - The core point of the article is that Tianyao Pharmaceutical (SH 600488) announced the results of its board meeting held on November 28, 2025, which included discussions on the performance evaluation and compensation of senior management for the year 2024 [1] - For the first half of 2025, Tianyao Pharmaceutical's revenue composition was as follows: steroid hormones accounted for 62.47%, formulations for 27.95%, amino acid raw materials for 8.98%, and other businesses for 0.57% [1] - As of the report date, Tianyao Pharmaceutical's market capitalization was 4.7 billion yuan [1]